Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Milestone ScientificMLSS -10.47%37 Debt-to-Equity is 0.18 as of Jun. 2026, which is 260% above its 10-year median of 0.05. GuruFocus rates MLSS with a GF Score™ of 37/100 and a GF Value™ of $0.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 702 Medical Devices & Instruments companies, Milestone Scientific ranks better than 55.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Milestone Scientific's Debt-to-Equity or its related term are showing as below:
MLSS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04 Med: 0.05 Max: 1.27
Current: 0.18
During the past 13 years, the highest Debt-to-Equity Ratio of Milestone Scientific was 1.27. The lowest was -0.04. And the median was 0.05.
MLSS's Debt-to-Equity is ranked better than 55.27% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs MLSS: 0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Milestone Scientific Debt-to-Equity Related Terms
Milestone Scientific Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Milestone Scientific's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLSS vs NEPH, HBIO, POCI: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Milestone Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Scientific Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Milestone Scientific's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Milestone Scientific's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Scientific (MLSS) has a Debt-to-Equity of 0.18 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Milestone Scientific and its competitors. This is 260% above median its historical median of 0.05. According to the industry distribution chart, Milestone Scientific ranks #314 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is Milestone Scientific's Debt-to-Equity too high?
Milestone Scientific's current Debt-to-Equity of 0.18 is 260% above median its 10-year median of 0.05. The Medical Devices & Instruments industry median Debt-to-Equity is 0.22. Milestone Scientific's value of 0.18 is 18.2% below this industry median. Based on the distribution chart, Milestone Scientific ranks #314 out of 702 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Milestone Scientific has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Milestone Scientific's Debt-to-Equity compare to NEPH and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Milestone Scientific ranks #314 out of 702 companies for Debt-to-Equity. This puts Milestone Scientific in the upper half of its industry. The industry median Debt-to-Equity is 0.22. Milestone Scientific's value of 0.18 is 18.2% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 0.22, Milestone Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Scientific's current Debt-to-Equity of 0.18 is 18.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Milestone Scientific and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Scientific's current Debt-to-Equity is 0.18, which is 260% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Scientific stock overvalued right now?
Based on GuruFocus' analysis, Milestone Scientific (MLSS) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.60, compared to a current price of $0.50 — trading 17.5% below its estimated fair value. The current Debt-to-Equity is 0.18, which is 260% above median its 10-year median of 0.05 and 18.2% below the Medical Devices & Instruments industry median of 0.22. Milestone Scientific's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Milestone Scientific (MLSS), the current Debt-to-Equity is 0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Milestone Scientific (MLSS) Overvalued in 2026?
Based on GuruFocus' analysis, Milestone Scientific stock appears to be undervalued.
The current stock price of $0.50 is trading 17.5% below its estimated GF Value™ of $0.60.
GuruFocus considers Milestone Scientific to be Modestly Undervalued.
Key valuation signals for MLSS:
Debt-to-Equity: 0.18 (260% above median its 10-year median of 0.05)
GF Value™: $0.60 vs. price of $0.50 (17.5% below fair value)
Industry Position: 18.2% below the Medical Devices & Instruments median (#314 of 702)
No single metric tells the full story. See the MLSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
37GF Score
Get the complete analysis for MLSS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLSS has been successfully added to your 
